Drug Profile
Pagibaximab
Alternative Names: A110; BSYX-A110; HU 96110Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Applied Molecular Evolution; Biosynexus
- Developer Biosynexus
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Lipoteichoic acid inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Staphylococcal infections
Most Recent Events
- 07 Dec 2010 Biosynexus completes enrolment in its phase II/III trial for Staphylococcal infections in USA (MAB-N007)
- 19 Jun 2007 MedImmune has been acquired by AstraZeneca
- 13 Jun 2006 This monoclonal antibody is still in active development